Skip to main content
    S

    Syndax Pharmaceuticals Inc (SNDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.13
    -0.32 (-3.39%)

    Market Cap: $850.77M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Syndax Pharmaceuticals Inc (SNDX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Syndax Pharmaceuticals (SNDX) to earn -$2.13 per share in the fiscal year ending Dec 31, 2026, on revenue of $316.36M. Of 12 analysts, 12 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 1.83, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy216.7%
    Buy1083.3%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    12

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 45.0%.

    Fiscal year ending Dec 31, 2026
    -$2.13
    EPS consensus, revenue $316.36M
    Fiscal year ending Dec 31, 2027
    -$0.78
    EPS consensus, revenue $458.76M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.13-$2.24 to -$1.967$316.36M$308.83M to $332.89M9
    Dec 31, 2027-$0.78-$1.96 to $0.4011$458.76M$402.01M to $614.97M11

    Quarterly Estimates

    The EPS consensus rises from -$0.50 for the quarter ending Dec 31, 2026 to -$0.28 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.50-$0.59 to -$0.2814$97.41M$85.26M to $134.27M13
    Mar 31, 2027-$0.28-$0.42 to -$0.083$95.95M$95.30M to $96.61M2

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 6 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202613
    Fiscal year ending Dec 31, 202712
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.91.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$2.13-$1.94-$1.95-$1.93-$1.91N/A
    Fiscal year ending Dec 31, 2027-$0.78-$0.73-$0.85-$0.82-$0.45N/A
    Quarter ending Mar 31, 2027-$0.28-$0.08-$0.07-$0.07-$0.07N/A

    Frequently Asked Questions About SNDX

    What is the SNDX stock forecast?

    Consensus analyst estimates put Syndax Pharmaceuticals's EPS at -$2.13 for the fiscal year ending Dec 31, 2026, on revenue of $316.36M. The consensus rating from 12 analysts is Buy.

    How do analysts rate SNDX stock?

    Of 12 analysts covering Syndax Pharmaceuticals, 2 rate it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from SNDX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.13, with estimates from -$2.24 to -$1.96 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.78, with estimates from -$1.96 to $0.40 from 11 analysts.

    What revenue do analysts expect from Syndax Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $316.36M, with estimates from $308.83M to $332.89M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $458.76M, with estimates from $402.01M to $614.97M.

    How many analysts cover SNDX?

    12 analysts rate Syndax Pharmaceuticals stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.